OPTN / Optineurin · IHC design guide

Design Immunohistochemistry for OPTN

Plan chromogenic OPTN IHC in paraffin sections with the catalog antibody at 2–5 μg/ml (datasheet: PB9343). Assess cytoplasmic staining in glandular and brain cells (HPA tissue IHC), and account for the reported low consistency between antibody staining and RNA expression (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for OPTN (IHC for OPTN): expected localisation Cytoplasmic tissue staining (HPA tissue IHC); perinuclear and Golgi localisation (UniProt), antibody PB9343, validated IHC image, and IHC protocol steps — Printable **OPTN** IHC protocol sheet — expected localisation Cytoplasmic tissue staining (HPA tissue IHC); perinuclear and Golgi localisation (UniProt), antibody PB9343, controls and protocol steps. Open the full OPTN IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

OPTN Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic tissue staining (HPA tissue IHC); perinuclear and Golgi localisation (UniProt)
	Staining pattern	Cytoplasmic signal in glandular, neuronal and glial cells (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet PB9343)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	None in HPA (detected in all 45 tissues); use no-primary + isotype controls

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections. (standard IHC practice; not target-specific)
	Caveat	Staining has low consistency with RNA expression (HPA tissue IHC)
	Regulation	RNA enriched in skeletal muscle, tongue (HPA tissue RNA)
	Isoform / epitope	3 isoforms; no extracellular domain; epitope map unknown (UniProt)

Section 1

Recommended OPTN IHC & IF Protocols

Compare the catalog antibody’s IHC-P protocol with 4 published OPTN IHC protocols (PMC7940236; PMC4470809; PMC5833650; PMC9167278).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human gall bladder adenosquamous carcinoma tissue; fixative not specified (datasheet PB9343)
Fixation	Image fixative and duration unreported (datasheet PB9343); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet PB9343); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB9343)
Primary antibody	Rabbit anti-OPTN, 2-5 μg/ml (datasheet PB9343)
Primary incubation	Overnight at 4 °C (datasheet PB9343)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9343)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	OPTN-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control.

💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval (datasheet: PB9343); for carcinoma sections, compare the published Tris-EDTA pH 9.0 method (PMC7940236).

Section 2

What Is the Expected OPTN Staining Pattern?

OPTN should show predominantly cytoplasmic staining, with possible perinuclear or Golgi-associated accentuation; it has no transmembrane segment (UniProt Q96CV9 localization and topology). HPA reports general cytoplasmic IHC expression and high staining in several glandular and epithelial populations, as well as selected neural cells (HPA: tissue IHC). Its tissue-IHC reliability is Approved, with low consistency between antibody staining and RNA expression (HPA: tissue IHC).

What am I looking at on my slide?
Cytoplasmic staining in adrenal, appendix, breast or colon glandular cells; or bronchial respiratory epithelium.	This fits the reported high-staining cell populations and general cytoplasmic profile (HPA: tissue IHC). Judge the signal in the named cells, rather than treating staining anywhere in the section as confirmation.
Cytoplasmic staining in caudate glial cells, cerebellar granular-layer cells or cerebral-cortex neurons.	These are additional reported high-staining populations (HPA: tissue IHC). Compare the observed cell type with the relevant HPA entry; a positive region alone does not establish the expected cellular pattern.
Predominantly nuclear, sharply membrane-bound or exclusively extracellular staining.	That distribution conflicts with OPTN's reported cytoplasmic, perinuclear, Golgi and vesicular locations and absence of a transmembrane segment (UniProt Q96CV9). Treat it as a possible artefact and check controls before assigning it to OPTN.
Strong signal in cells outside the reported positive population, or widespread diffuse staining over tissue and empty areas.	The cell mismatch raises concern for cross-reactivity or endogenous detection activity; diffuse signal also suggests nonspecific background (general IHC practice). HPA supplies no negative-cell list here, so an unlisted cell cannot be declared OPTN-negative from this record.
No discernible cytoplasmic signal in an HPA high-staining cell population.	First consider a failed or insensitive IHC run, while allowing for specimen differences (general IHC practice; HPA: high staining in listed cells). The Approved HPA rating has low agreement with RNA data, so one blank section does not settle OPTN absence (HPA: tissue IHC).

💡Expected OPTN appearanceCall a result positive when named HPA high-staining cells show clear cytoplasmic signal, potentially with perinuclear accentuation; isolated nuclear or extracellular colour is suspect (HPA: tissue IHC; UniProt Q96CV9 localization).

How each factor affects the staining
Compartment and topology	OPTN is reported in cytoplasm, perinuclear region, Golgi, vesicles and recycling endosomes, with no transmembrane segment (UniProt Q96CV9). At light-microscope IHC resolution, cytoplasmic staining is the primary call; do not require a distinct organelle pattern.
Tissue reference and evidence limit	HPA lists high staining in specific glandular, respiratory and neural cell populations, but supplies no negative tissues in this payload (HPA: tissue IHC). Its Approved rating includes low consistency with RNA expression, so use the listed patterns as comparators rather than absolute cutoffs (HPA: tissue IHC).
Antibody validation	All 3 listed antibodies have Approved IHC status; none is listed as IHC Enhanced (HPA: antibody validation). An Enhanced ICC rating for HPA003279 or HPA003360 applies to ICC, not automatically to paraffin-section IHC (HPA: antibody validation).
Isoforms and epitope coverage	UniProt lists 3 OPTN isoforms (UniProt Q96CV9). No antibody epitope or isoform coverage is supplied, so the IHC signal cannot be assigned to a particular isoform from this record.
IF/ICC Q: What localisation should be expected?	A: HPA describes OPTN as mainly cytosolic in ICC-IF, consistent with UniProt's broader cytoplasmic localisation (HPA: subcellular ICC-IF; UniProt Q96CV9). That observation informs compartment interpretation; it is not a paraffin-IHC protocol or proof of identical staining in tissue sections.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
The expected positive cells are blank.	The staining run may have failed or the antibody may be too insensitive under the chosen conditions (general IHC practice).	Check a listed HPA high-staining tissue in the same run and verify that detection and counterstain worked; then review the catalog antibody's IHC-P instructions (HPA: tissue IHC; general IHC practice).
Signal appears only in nuclei or along cell borders.	This conflicts with the reported OPTN distribution and topology (UniProt Q96CV9).	Compare with a negative reagent control and inspect whether the signal tracks tissue edges or other artefacts before scoring cells (general IHC practice).
Colour covers the section or persists outside cells.	Nonspecific binding, incomplete washing or endogenous detection activity can produce background (general IHC practice).	Inspect the negative reagent control; review blocking, washes and detection controls, then score only distinct cellular staining (general IHC practice).
A strongly stained cell type does not match the HPA entry for that tissue.	Cross-reactivity or endogenous detection activity is possible; HPA reports high staining by cell type, not merely by organ (HPA: tissue IHC; general IHC practice).	Recheck cell identity on the counterstain and compare a negative reagent control. Treat unlisted cells as unresolved, since this payload has no HPA negative list (HPA: tissue IHC).
A faint cytoplasmic wash is difficult to score.	Low contrast can obscure a cellular pattern (general IHC practice); the HPA record does not define a numeric OPTN intensity cutoff (HPA: tissue IHC).	Compare the named positive cells with background and the negative reagent control in the same run; record equivocal staining instead of forcing a positive call (general IHC practice).
Only one specimen shows a different pattern from the reference.	HPA tissue-IHC staining has low consistency with RNA expression, and its listed positives are observations rather than universal thresholds (HPA: tissue IHC).	Review the cell type and compartment, repeat with a listed positive comparator, and report the discordance without inferring OPTN absence or a new localization from one section (HPA: tissue IHC; UniProt Q96CV9 localization).

Source: UniProt Q96CV9 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing OPTN staining

IHC analysis of Optineurin using anti-Optineurin antibody (PB9343). Optineurin was detected in a paraffin-embedded section of human gall bladder adenosquamous carcinoma tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-Optineurin Antibody (PB9343) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

PB9343 · IHCIHC analysis of Optineurin using anti-Optineurin antibody (PB9343). Optineurin was detected in a paraffin-embedded section of human gall bla

IHC analysis of Optineurin using anti-Optineurin antibody (PB9343). Optineurin was detected in a paraffin-embedded section of mouse brain tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-Optineurin Antibody (PB9343) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

PB9343 · IHCIHC analysis of Optineurin using anti-Optineurin antibody (PB9343). Optineurin was detected in a paraffin-embedded section of mouse brain ti

M00952-2 · IHCMouse brain was stained with Anti-Optineurin rabbit antibody

M00952-2 · IHCHuman colon carcinoma was stained with Anti-Optineurin rabbit antibody

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000123240-OPTN/tissue/cerebral+cortex#imid_4998028

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000123240-OPTN/tissue/colon#imid_4997938

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000123240-OPTN/tissue/liver#imid_4997955

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000123240-OPTN/tissue/kidney#imid_4997948

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB019303; green = OPTN, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for OPTN IHC & IF

🧪Run appendix first and score its glandular cells for OPTN staining (HPA: High in appendix glandular cells). HPA detects OPTN in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and treat cells showing counterstain alone as apparent low-staining cells rather than validated internal negatives (HPA: detected in all 45 tissues).

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: None in HPA: OPTN is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show OPTN in A-431, U-251MG, U2OS, NIH 3T3, with annotated localisation: Cytosol (enhanced) (HPA subcellular).

Technical controls: Include a secondary-only slide, an isotype-matched rabbit IgG control matched to the primary antibody’s clonality where known, and an identically processed OPTN-knockout specimen as a biological negative (selected PB9343 caption: rabbit primary antibody). Quench endogenous peroxidase and check for endogenous biotin background in appendix sections because the reported detection uses a biotin-based complex and DAB (selected PB9343 caption: biotinylated secondary, SABC, DAB).

⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected PB9343 paraffin-section caption does not state the fixative (selected PB9343 caption: fixative unreported). The reported IHC procedure uses heat retrieval in EDTA at pH 8.0, but the evidence does not establish that retrieval is required; it also does not establish that frozen sections or IF are easier (selected PB9343 caption: heat retrieval in EDTA). In appendix, inflammatory cells may add endogenous peroxidase background to DAB staining, so assess them against the secondary-only control (standard IHC practice).

HPA tissue IHC evidence for OPTN

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Appendix	Glandular cells	High	Protein (IHC)	HPA →
Breast	Glandular cells	High	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	High	Protein (IHC)	HPA →
Caudate	Glial cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
None in HPA: OPTN is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

Section 3

Advanced OPTN IHC Tips

Troubleshoot OPTN staining in paraffin section IHC by checking retrieval, staining controls, cellular location, and how positive cells are scored.

Which retrieval condition should I try first for OPTN IHC?

Start with heat mediated retrieval in EDTA at pH 8.0 (datasheet PB9343). The selected paraffin section image used that condition before incubation with 2 μg/ml primary antibody overnight at 4°C, so assess retrieval alongside the documented antibody condition (datasheet PB9343). If staining is weak, compare a shorter and longer heating cycle on matched sections while holding antibody concentration, detection, and development constant (standard IHC practice). Inspect tissue integrity and background after each cycle; stronger staining alone does not establish specificity, particularly when the tissue IHC profile has low consistency with RNA expression (HPA tissue IHC).

How can I troubleshoot weak OPTN staining related to fixation?

The selected paraffin section caption does not state a fixative, so target specific fixation sensitivity is unknown (datasheet PB9343). Record each specimen’s fixative and fixation time, then compare matched sections processed with the same EDTA pH 8.0 retrieval and 2 μg/ml primary antibody conditions (datasheet PB9343; standard IHC practice). Examine whether weak staining tracks with tissue processing history while a concurrently stained control section remains interpretable (standard IHC practice). Do not assign the loss to OPTN phosphorylation or its lack of a transmembrane segment: neither establishes a fixation effect in these sections (UniProt Q96CV9; datasheet PB9343).

Where should convincing OPTN staining appear in tissue sections?

Expect predominantly cytoplasmic staining when assessing OPTN IHC, consistent with its general tissue profile (HPA tissue IHC). Perinuclear concentration can be plausible because OPTN associates with the Golgi and trans Golgi network, and it can also occupy cytoplasmic vesicles and recycling endosomes (UniProt Q96CV9). Score cellular staining separately from diffuse extracellular deposit or staining confined to a cut edge, and check the corresponding morphology on the counterstained section (standard IHC practice). A punctate pattern deserves comparison with appropriate compartment markers before calling it autophagy related, because LC3 positive vesicle localisation is described upon autophagy induction (UniProt Q96CV9).

Could isoforms or epitope masking explain discordant OPTN staining?

OPTN has 3 annotated isoforms, but the supplied antibody caption does not identify the recognized epitope or establish isoform coverage (UniProt Q96CV9; datasheet PB9343). Check the antibody’s epitope documentation before interpreting a negative section as absence of all isoforms, and keep retrieval and detection conditions matched across comparisons (standard IHC practice). OPTN has annotated phosphoserines at positions 177, 198, 342, and 526; the payload does not show whether these modifications affect this antibody (UniProt Q96CV9; datasheet PB9343). If patterns disagree between antibodies, compare their documented epitope regions and staining controls before attributing the difference to splicing or phosphorylation (standard IHC practice).

How should I investigate OPTN localisation by multiplex IF?

For the separate IF workflow, pair OPTN with a marker defining the cell population under study and a nuclear counterstain, then assess signal within identified cells (standard IF practice). Select spectrally separated fluorophores after inspecting unstained tissue autofluorescence, and include single stain controls to check bleed through (standard IF practice). Because OPTN is described in cytoplasm, Golgi associated regions, and cytoplasmic vesicles without a transmembrane segment, optimise permeabilisation for access to intracellular epitopes rather than assuming a surface staining workflow will expose them (UniProt Q96CV9; standard IF practice). The supplied IHC caption does not establish an IF fixation condition or an IF validated antibody concentration (datasheet PB9343).

What should I check when OPTN IHC has diffuse background?

Compare the test section with a no primary control to identify signal arising from detection reagents or tissue rather than primary antibody binding (standard IHC practice). In a biotin based DAB workflow, assess endogenous biotin and endogenous peroxidase contributions, and apply the appropriate blocking steps before interpreting brown signal (datasheet PB9343; standard IHC practice). The documented section used 10% goat serum blocking and 2 μg/ml primary antibody overnight at 4°C, giving concrete starting conditions for a controlled titration (datasheet PB9343). If background persists, adjust primary concentration or development time one variable at a time and preserve a comparable positive control (standard IHC practice).

How should I quantify OPTN staining across specimens? ⚠ ANSWER MARKED FOR VERIFICATION

Define the tissue compartment and eligible cells before scoring, then use the same regions and exclusion criteria across specimens (standard IHC practice). Report the percentage of positive cells and an intensity based H score for cellular OPTN signal, or count positive cells per mm² when spatial density is the endpoint (standard IHC practice). Normalise counts to evaluable tissue area or the relevant cell population, and record how necrotic, folded, and edge regions were excluded (standard IHC practice). Keep retrieval, staining, imaging, and scoring thresholds consistent; interpret between tissue differences cautiously because HPA reports low consistency between antibody staining and RNA expression (HPA tissue IHC; standard IHC practice).

How can I distinguish genuine OPTN positivity from staining artefact?

Give greatest weight to reproducible cellular cytoplasmic signal, with possible perinuclear or vesicular concentration, because those locations fit the reported OPTN distribution (HPA tissue IHC; UniProt Q96CV9). Check whether stained cells match the section morphology and whether the pattern repeats away from cut edges, folds, and necrotic areas (standard IHC practice). Treat isolated nuclear staining or a deposit outside intact cells as suspect until an independent control supports it, since the supplied localisation evidence places OPTN mainly in the cytoplasm (HPA subcellular; standard IHC practice). Compare no primary and peroxidase blocked controls when DAB signal could reflect endogenous enzyme activity (standard IHC practice).

Boster reagents

Best OPTN / Optineurin IHC Antibodies

Both anti-OPTN antibodies list IHC for human, mouse and rat samples; tissue images support those species for PB9343 and human and mouse for M00952-2 (catalog: applications, reactivity, image alts).

Real IHC data

Anti-Optineurin/OPTN Antibody ®

Cat # PB9343

View product →

Real IHC data Mouse brain was stained with Anti-Optineurin rabbit antibody

Anti-Optineurin Rabbit Monoclonal Antibody

Cat # M00952-2

View product →

PB9343 has IHC images from human gall bladder adenosquamous carcinoma and mouse and rat brain (catalog: PB9343 IHC image alts). M00952-2 has IHC images from human colon carcinoma and human and mouse brain, and lists IF as an application without an IF image (catalog: M00952-2 image alts, applications).

Which to pick: Choose PB9343 for paraffin-section IHC when its documented conditions are useful: the caption reports EDTA retrieval at pH 8.0 and 2 μg/ml antibody; the fixative is unreported (catalog: PB9343 IHC image alt). For IF, choose M00952-2 because it lists IF at 1:200–1:1000 and is a rabbit monoclonal antibody; ICC-specific validation is unreported (catalog: M00952-2 applications, dilution, title). For human, mouse or rat tissue IHC, both list reactivity, while PB9343 alone supplies IHC images for all three species (catalog: reactivity, IHC image alts).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q96CV9 (OPTN_HUMAN, Optineurin).
Human Protein Atlas. OPTN tissue IHC expression (reliability: Approved).
Human Protein Atlas. OPTN subcellular location (ICC-IF): Mainly localized to the cytosol..
Human Protein Atlas. OPTN antibody validation summary (3 antibodies).
Suppression of optineurin impairs the progression of hepatocellular carcinoma through regulating mitophagy. Cancer medicine 2021 — PMC7940236.
Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta neuropathologica 2015 — PMC4470809.
Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy. Cell death & disease 2018 — PMC5833650.
OPTN attenuates the neurotoxicity of abnormal Tau protein by restoring autophagy. Translational psychiatry 2022 — PMC9167278.
PubMed PMID:9488477 — UniProt-cited evidence.
PubMed PMID:11834836 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.